A Phase Ib/II study of serabelisib in combination with canagliflozin (an SGLT-2 inhibitor) in advanced solid tumors with PIK3CA mutations or KRAS mutations, including BC, is testing the efficiency of this association (NCT04073680). This evidence concerns the gene SLC5A2 and breast cancer.